Business
Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial With Alberta Innovates Grant; Announces Stock Option and DSU Grants, and Proposed Issuance of Securities for Debt
CALGARY, ALBERTA - March 4, 2026 (NEWMEDIAWIRE) - Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) (the "Company" or "Voyageur"), a Canadian developer of pharmaceutical-grade barium and iodine for medical imaging contrast media, is pleased...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"CALGARY, ALBERTA - March 4, 2026 (NEWMEDIAWIRE) - Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) (the "Company" or "Voyageur"), a Canadian developer of pharmaceutical-grade barium and iodine for medical imaging contrast media, is pleased to announce independent laboratory test results for its barium sulfate active pharmaceutical ingredient (API). This testing was completed as part of the Alberta Innovates AICE-Market Access Program as previously announced on February 5 and March 4, 2025. Voyageur anticipates completing the first stage of this project after manufacturing batches of new product using Frances Creek barium sulfate and then moving to stage two, unlocking additional non-dilutive funding. The API barite was sourced from the Company's Frances Creek barite property in British Columbia. Results achieved purity, full USP compliance, successful micronization, and management of Voyageur believes the upcoming patient trial may confirm a path to commercial use of natural barium sulfate API.","length":1044,"tagName":"p"},{"type":"text","content":"Purity Exceeding Pharmaceutical Grade, 98.8% BaSO4","length":50,"tagName":"p"},{"type":"text","content":"Moving on to Stage 2 of the Alberta Innovates AICE-Market Access Program","length":72,"tagName":"p"},{"type":"text","content":"Testing by SGS Laboratories, located in Mississauga, Ontario ("SGS"), confirmed purity, with % BaSO4 assay results ranging from 98.1% to 99.4% across multiple samples, above the USP monograph requirement of 97.5%. Several batches achieved 99.1% to 99.4% purity, with an average grade of 98.8%. All samples fully passed the complete suite of USP monograph tests, including identification, pH, loss on drying, limit of soluble barium salts (NMT 0.001%), acid-soluble substances, sulfides, and microbiological requirements. USP elemental impurities testing showed heavy metal levels significantly lower than the USP specifications. The processed barite achieved 1-micron and 10-micron particle sizes. Processing trials at Sturtevant Inc. using pharmaceutical-grade micronizing equipment demonstrated that the material processes efficiently into ultra-fine particles. Multiple test runs produced excellent particle size distributions, with d50 values of 1.1-1.9 m and d90 values as low as 2.5 m under optimal conditions. All micron...